Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27478848 | 1.00 | MAOA (0.58) | MAOAHRH1HTR2ASIGMAR1DNM1 | |
| SCHEMBL3581333 | 0.98 | MAOA (0.60) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL309769 | 0.91 | MAOA (0.50) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL11690401 | 0.88 | SIGMAR1 (0.41) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL11803736 | 0.85 | MAOA (0.40) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL9350714 | 0.83 | MAOA (0.71) | MAOAHRH1HTR2ADNM1CA12 | |
| SCHEMBL7510277 | 0.82 | HRH1 (0.38) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL2138046 | 0.82 | HRH1 (0.38) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL4629583 | 0.82 | HRH1 (0.38) | MAOAHRH1HTR2ASIGMAR1 | |
| SCHEMBL758587 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1537913-B1 | PALLADIUM CATALYST COMPOSITION | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1228061-A4 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND METHODS OF MAKING AND USING DIPEPTIDYL PEPTIDASE IV INHIBITORS | GUILFORD PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1228061-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND METHODS OF MAKING AND USING DIPEPTIDYL PEPTIDASE IV INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034594-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND METHODS OF MAKING AND USING DIPEPTIDYL PEPTIDASE IV INHIBITORS | GUILFORD PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | MAOA 1512/4885HRH1 2656/4885HTR2A 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.